Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELARA: Long-Term Safety, Tolerability, and Efficacy of OV101 in Angelman Syndrome
2019-004478-24Phase 3Completed
- Sponsor
- Ovid Therapeutics
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gaboxadol in Angelman syndrome (AS), sponsored by Ovid Therapeutics. Primary endpoint: Safety endpoints. Started Feb 2020; status: completed.
02
Drugs
gaboxadol
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on 2019-004478-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004478-24.